Treatment For Autism to Start Trials After Successful Testing, Good For Alzheimer’s Too
By McKinley Corbley
A potential treatment for the most common form of autism is on its way to human trials after it was proven successful in mice.
Drug developer Tetra Discovery Partners has received clearance from the FDA to begin phase two of their testing for a treatment called BPN14770.
The therapeutic agent could be used to treat Fragile X syndrome: a genetic form of autism that reportedly affects 1 in 4,000 to 5,000 males and one in 6,000 to 8,000 females. There is currently no treatment for the condition.